Rowland Carmichael Advisors’s Edwards Lifesciences EW Stock Holding History

Rowland Carmichael Advisors’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	$224K	Buy	+2,458	New	+$204K	0.07%	278

Other funds holding EW

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

KBC Group Brussels, Belgium $39.9B AUM 29.7% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Rowland Carmichael Advisors's EW Position: Q4 2020 in Review

Rowland Carmichael Advisors opened a new position in Edwards Lifesciences (EW) in Q4 2020: 2,458 shares worth $224K. The stake represents 0.07% of the portfolio and ranks #278 among its holdings.

1,158 funds tracked by Wall St. Rank hold EW as of Q4 2020.

Rowland Carmichael Advisors held 2,458 shares of Edwards Lifesciences worth $224K as of Q4 2020.
Edwards Lifesciences was a new Rowland Carmichael Advisors position in Q4 2020.
Edwards Lifesciences made up 0.07% of Rowland Carmichael Advisors's portfolio in Q4 2020, its #278 holding.
1,158 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q4 2020.

Based on Rowland Carmichael Advisors's 13F filing for Q4 2020, filed 15 Jan 2021.